Orobika Tablet 10/40 mg
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.
MFDS item code 202003042 · Approved 2020.04.24
This product's status changed to Expired on 2025.04.24. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively lower and control blood pressure in patients with essential hypertension whose blood pressure is not well managed with monotherapy of amlodipine or olmesartan medoxomil.
Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine must not be administered to patients with severe hepatic impairment. (Refer to “2. Patients Who Must Not Receive This Medicine” under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, take the patient’s renal or cardiac function and comorbid diseases into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.
∘Pediatric patients: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medication may cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be administered to individuals with allergies to the main ingredients or similar medications, to pregnant or breastfeeding women, to patients with severe liver disease, heart valve issues, biliary obstruction, patients on renal dialysis, patients in shock, certain diabetic patients, or patients with severely impaired kidney function. Caution should be exercised in patients with low blood volume or sodium levels, as hypotension may occur, particularly during the initial administration. Patients with significant vascular dilation or heart disease may also need careful monitoring, as rapid vascular expansion can lead to hypotension. In patients with impaired kidney function or liver dysfunction, caution should be exercised as this medication can affect the kidneys or liver. Side effects such as dizziness, headache, hypotension, nausea, swelling, and others may occur during treatment; if unusual symptoms persist, consultation with healthcare professionals is advised. This medication should not be used during pregnancy, and breastfeeding women should either discontinue the medication or stop breastfeeding due to the potential transmission of the drug to the infant. Safety and efficacy have not been established for pediatric patients under 18 years of age. Elderly patients may have impaired liver or kidney function, so dosage adjustments and careful monitoring are necessary. In the case of overdose, hypotension and cardiac arrhythmias may occur, necessitating immediate medical treatment.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air and moisture, at a temperature between 1 and 30 degrees Celsius. Proper storage preserves the medication's efficacy.
Reddish-brown round film-coated tablet
30 tablets/box [(10 tablets/PTP X 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.